GlassScriptPhysician profile
Soo Y Kim
NPI 1205924800
$6,388.45
in general payments reported to CMS, 2019-2025
31 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $618 · 2021: $641 · 2022: $1,147 · 2023: $1,174 · 2024: $1,142 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,363 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,363.03 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,253.65 | 2019-2025 | |
| Boston Scientific Corporation | $849.92 | 2020-2025 | Wavewriter Alpha Prime 16, General - Hemostasis, Farapulse |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.24 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $456.99 | 2019-2025 | Livdelzi |
| Janssen Biotech, INC. | $406.13 | 2019-2025 | Stelara, Tremfya, Simponi |
| Janssen Scientific Affairs, LLC | $208.08 | 2021-2022 | |
| Madrigal Pharmaceuticals | $202.69 | 2025 | Rezdiffra |
| Takeda Pharmaceuticals U.S.A., INC. | $172.93 | 2019-2022 | |
| Celgene Corporation | $146.01 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $128.34 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $97.69 | 2022 | |
| Cook Medical LLC | $96.83 | 2025 | Echotip Insight |
| Intercept Pharmaceuticals, INC. | $95.45 | 2020-2024 | Ocaliva |
| Qol Medical, LLC | $90.22 | 2022-2023 | Sucraid |
| Covidien LP | $69.24 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $66.26 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $56.43 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $51.39 | 2019-2022 | |
| Allergan, INC. | $51.08 | 2019-2020 | |
| Lilly USA, LLC | $48.26 | 2024 | Omvoh |
| Genzyme Corporation | $43.07 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $40.12 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $31.09 | 2019-2023 | Sutab |
| Daiichi Sankyo INC. | $24.79 | 2019 | |
| Vivus LLC | $24.17 | 2022 | |
| Novo Nordisk INC | $22.71 | 2025 | Wegovy |
| Shionogi INC | $20.23 | 2019 | |
| Redhill Biopharma INC. | $16.84 | 2020 | |
| Alfasigma USA, INC. | $15.60 | 2020 | |
| Pfizer INC. | $14.59 | 2023 | |
| Endo Pharmaceuticals INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soo Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.